Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
Authors
Keywords
Cholangiocarcinoma, Afatinib, BIBW 2992, Biomarkers, EGFR, panHER inhibition
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-01-11
DOI
10.1186/s12885-018-5223-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer
- (2018) Renuka V. Iyer et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)
- (2018) Michael Stahl et al. EUROPEAN JOURNAL OF CANCER
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- (2015) M. Schuler et al. ANNALS OF ONCOLOGY
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
- (2015) Y. Kobayashi et al. CLINICAL CANCER RESEARCH
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C
- (2014) Qiang Du et al. CANCER SCIENCE
- Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
- (2014) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
- (2013) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
- (2011) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
- (2011) N Ioannou et al. BRITISH JOURNAL OF CANCER
- The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
- (2011) Hyun-Jin Nam et al. INVESTIGATIONAL NEW DRUGS
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
- (2009) A D Wagner et al. BRITISH JOURNAL OF CANCER
- Leptin Enhances Cholangiocarcinoma Cell Growth
- (2008) G. Fava et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Leptin–leptin receptor are involved in angiogenesis in human hepatocellular carcinoma
- (2008) Domenico Ribatti et al. PEPTIDES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now